10x Genomicsの発行済株式数
10x Genomicsの発行済株式数は何ですか。
10x Genomics, Inc.の発行済株式数は95.596Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
NASDAQのセクタHealth Careにおける発行済株式数の企業と比べる10x Genomics
10x Genomicsは何をしますか。
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10x Genomicsと類似の発行済株式数
- discoverIE plcの発行済株式数は95.456Mです。
- First Bancorpの発行済株式数は95.482Mです。
- Proactis Plcの発行済株式数は95.533Mです。
- West Cobar Metals Ltdの発行済株式数は95.534Mです。
- Ocean Power Technologiesの発行済株式数は95.574Mです。
- Third Point Reinsurance Ltdの発行済株式数は95.583Mです。
- 10x Genomicsの発行済株式数は95.596Mです。
- Pagerduty Incの発行済株式数は95.600Mです。
- Michelmersh Brick Plcの発行済株式数は95.633Mです。
- Surge Battery Metalsの発行済株式数は95.656Mです。
- Eros International Mediaの発行済株式数は95.727Mです。
- Propell Ltdの発行済株式数は95.790Mです。
- Acco Brandsの発行済株式数は95.798Mです。